Adaptogenics Health Corp. Announces Non-Brokered Private Placement
Adaptogenics Health Corp. intends to raise up to $625,000 through a non-brokered private placement of units to fund its business initiatives.
Stocks · News reference
Adaptive Biotechnologies announced that its clonoSEQ test for measurable residual disease (MRD) will be featured in approximately 100 abstracts at the 68th Annual Meeting of the American Society of Hematology (ASH).
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Adaptogenics Health Corp. intends to raise up to $625,000 through a non-brokered private placement of units to fund its business initiatives.
Adaptogenics Health Corp. submitted formal comments to the U.S. Department of Health and Human Services regarding the regulation of peptide bulk drug substances in compounding.
Adaptogenics Health Corp. has been approved to uplist its shares from the OTC Pink market to the OTCQB Venture Market, effective November 11, 2026.
Adaptive Biotechnologies Corporation announced its scheduled participation in upcoming investor conferences, including the Jefferies Global Healthcare Conference.
Guggenheim has maintained its 'Buy' rating on Adaptive Biotechnologies, as reported on November 10, 2026.